Business Description
Integral Diagnostics Ltd
ISIN : AU000000IDX2
Description
Integral Diagnostics is Australia's fourth-largest diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 1.19 | |||||
| Debt-to-EBITDA | 53.14 | |||||
| Interest Coverage | 2.48 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.84 | |||||
| Beneish M-Score | -2.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.4 | |||||
| 3-Year EBITDA Growth Rate | -59.5 | |||||
| 3-Year EPS without NRI Growth Rate | 195 | |||||
| 3-Year FCF Growth Rate | -9.4 | |||||
| 3-Year Book Growth Rate | 0.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 33.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 21.04 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.84 | |||||
| 9-Day RSI | 42.04 | |||||
| 14-Day RSI | 44.29 | |||||
| 6-1 Month Momentum % | 11.11 | |||||
| 12-1 Month Momentum % | 51.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.87 | |||||
| Quick Ratio | 0.85 | |||||
| Cash Ratio | 0.5 | |||||
| Days Inventory | 28.41 | |||||
| Days Sales Outstanding | 18.01 | |||||
| Days Payable | 259.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.02 | |||||
| 3-Year Dividend Growth Rate | -13.9 | |||||
| Forward Dividend Yield % | 2.02 | |||||
| 5-Year Yield-on-Cost % | 1.21 | |||||
| 3-Year Average Share Buyback Ratio | -5.1 | |||||
| Shareholder Yield % | 2.28 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.12 | |||||
| Operating Margin % | 8.98 | |||||
| Net Margin % | -12.92 | |||||
| FCF Margin % | 9 | |||||
| ROE % | -18.67 | |||||
| ROA % | -7.82 | |||||
| ROIC % | 5.87 | |||||
| ROC (Joel Greenblatt) % | -14.52 | |||||
| ROCE % | -5.8 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 26.82 | |||||
| PS Ratio | 1.43 | |||||
| PB Ratio | 2.22 | |||||
| Price-to-Free-Cash-Flow | 15.86 | |||||
| Price-to-Operating-Cash-Flow | 10.14 | |||||
| EV-to-EBIT | -34.45 | |||||
| EV-to-Forward-EBIT | 16.06 | |||||
| EV-to-EBITDA | 205.33 | |||||
| EV-to-Forward-EBITDA | 6.57 | |||||
| EV-to-Revenue | 2.94 | |||||
| EV-to-Forward-Revenue | 1.95 | |||||
| EV-to-FCF | 32.7 | |||||
| Price-to-Projected-FCF | 1.35 | |||||
| Earnings Yield (Greenblatt) % | -2.9 | |||||
| FCF Yield % | 3.96 | |||||
| Forward Rate of Return (Yacktman) % | -24.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Integral Diagnostics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 469.697 | ||
| EPS (TTM) (A$) | -0.26 | ||
| Beta | 0.59 | ||
| Volatility % | 26.02 | ||
| 14-Day RSI | 44.29 | ||
| 14-Day ATR (A$) | 0.101527 | ||
| 20-Day SMA (A$) | 2.94 | ||
| 12-1 Month Momentum % | 51.83 | ||
| 52-Week Range (A$) | 1.8 - 3.2 | ||
| Shares Outstanding (Mil) | 371.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Integral Diagnostics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Integral Diagnostics Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Integral Diagnostics Ltd Frequently Asked Questions
What is Integral Diagnostics Ltd(ASX:IDX)'s stock price today?
The current price of ASX:IDX is A$2.87. The 52 week high of ASX:IDX is A$3.20 and 52 week low is A$1.80.
When is next earnings date of Integral Diagnostics Ltd(ASX:IDX)?
The next earnings date of Integral Diagnostics Ltd(ASX:IDX) is 2025-02-20 Est..
Does Integral Diagnostics Ltd(ASX:IDX) pay dividends? If so, how much?
The Dividend Yield %  of Integral Diagnostics Ltd(ASX:IDX) is 2.02% (As of Today), Highest Dividend Payout Ratio of Integral Diagnostics Ltd(ASX:IDX) was 31.33. The lowest was 0.62. And the median was 0.75. The  Forward Dividend Yield % of Integral Diagnostics Ltd(ASX:IDX) is 2.02%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers